Bertrand Chauveau

Pathologist, Bordeaux University Hospital. Special interest in renal and transplant pathology.

[Lynn D. Cornell, M.D. @ldcornell]

The Banff 2024 meeting report is official! Link to the article (free access) is below- now get ready for the next Banff meeting, October 5-9, 2026, in beautiful Banff, Alberta, Canada!!
https://t.co/C0CkJ27vB3 @Renalpathsoc #renalpath

[American Journal of Transplantation @amjtransplant]

The AJT Banff Blog is live: https://t.co/OBIOf2dNaK

[Jasper Callemeyn @CallemeynJasper]

How many gene transcripts do you actually need to diagnose rejection phenotypes after kidney transplantation?

In our latest study in @KIReports, we found that the answer is surprisingly low!

https://t.co/eDgFZUlUAv

1/6

[Dina Zielinski @dinazielinski]

🧬Excited to share our new paper in @amjtransplant

“Molecular diagnosis of kidney allograft rejection using the B-HOT gene panel”

https://t.co/7RJ2oXSm5B

#MolecularDiagnostics #Transplantation

[Transplantation @TransplantJrnl]

Evolving the Banff Classification for Kidney Allograft Rejection. This review paper by @_B_Chauveau et al. reports that innovations are reshaping rejection diagnostics! #Transplantation #KidneyTransplant #Transplantation #TXPforAll https://t.co/8tadIi6R3w

[Sanjeev Sethi @SethiRenalPath]

We now have a mass spectrometry test available for membranous nephropathy (MN) antigens.

Started in 2017 with no lab/funding (& still no lab/major funding)-one at a time-we were able to discover majority of MN antigens.

It was an idea that worked out.

https://t.co/RYozLKTxXp

[NEJM @NEJM]

Kidney-transplant microvascular inflammation has a varied clinical presentation. This study of more than 16,000 biopsy specimens supports the recognition of additional rejection phenotypes to standardize diagnostics. https://t.co/FzWH6RAY28

#KidneyWk

[@HORUS_EU @HORUS_EUproject]

Dive into the #HORUS_CMV project with @hKminski, sharing insights on the team's efforts to understand #CMV's impact on transplant patients. Learn how they’re identifying signatures for personalised care to improve patient outcomes.

Watch the full video: https://t.co/BQEFJe2DWX

[Valentin Goutaudier @VGoutaudier]

Glad to share our @EUTRAIN_project paper published in @Kidney_Int! 🙌

🙏 to the amazing #consortium behind this #biomarker validation study funded by @EU_Commission @HorizonEU 🇪🇺

@AlexandreLoupy C. Lefaucheur @ParisTxGroup @ESOTtransplant @ttsorg

https://t.co/FIlS0GqNsZ

[Jean-Baptiste Gibier @Ijeb]

Unveiling glomerular gold in oxalate nephropathy - Kidney International https://t.co/K97sWS5HTU

[Lionel Couzi @LionelCouzi]

⚠️Happy to share our preliminary results on Imlifidase together with the French transplant community. 🙏🏻 @KamarNassim @dommibertrand @CaillardSophie @SFTfrancophone @SFTJuniors

More to come in 2025 🚨

https://t.co/GKhdZQmwzV

[Roslyn Mannon (moving to Bluesky as mannonmom) @mannonmom]

Abstract time for the #Banff2024 allograft pathology meeting 👇🏻👇🏻

[Bertrand Chauveau @_B_Chauveau]

@ChangUCanSpare @JZRenalPath @AskRenalPath Thank you for your advice! I will do it.

[Bertrand Chauveau @_B_Chauveau]

Male in his 80’s. Waldenström (no TTT). IgM kappa 10g/L
CKD with SCr 1.86 mg/dl. Prot 0.19 g/g
FFPE: ischemic glomeruli, stripped fibrosis 65% & >=cv2
Frozen: granular IgM kappa deposits in intimal fibrosis of an arcuate artery. No other deposits
1/2
#AskRenalPath
@AskRenalPath

[Bertrand Chauveau @_B_Chauveau]

@JZRenalPath @AskRenalPath Thank you for your insightful suggestions. I will at least ensure that the nephrologist carefully checks for a cryo and biological TMA features.

[Bertrand Chauveau @_B_Chauveau]

Congo red -.
EM: not available
What should I call this? Any advices? 🙏
2/2
#AskRenalPath
@AskRenalPath
@Tiff_Caza
@JZRenalPath
@MRabant
@CandiceRoufosse
@Ijeb
@ChangUCanSpare

[Lynn D. Cornell, M.D. @ldcornell]

More on “atypical anti-GBM disease”! Worldwide collaborative by B Chauveau et al published in @AJKDonline https://t.co/qZJHb6qP5j also see my commentary “Anti–GBM Disease: Broadening the Spectrum” https://t.co/UbJ5t77ku0 #renalpath @Renalpathsoc @MayoClinicNeph @MayoClinicPath

[Marion Rabant @MRabant]

Our study on post-transplant TMA is out! TMA is mostly driven by AMR and CNI toxicity but often due to multiple factors, with higher rates of complement pathogenic variants, and associated with a poor prognosis.

[Bertrand Chauveau @_B_Chauveau]

A nice collaborative work from the French Nephropathology Group!

[AJKD @AJKDonline]

Atypical Anti-Glomerular Basement Membrane Nephritis: A Case Series From the French Nephropathology Group

https://t.co/pEmvq21m4R

@_B_Chauveau @Ijeb @MorelAntoine9 @stephenmcadoo @nivallet @virginieroyal @DemoulinNathal2 @alexhertig @CandiceRoufosse @karine_renaudin @MRabant

[Bertrand Chauveau @_B_Chauveau]

@ClahsenMarian Very nice data, congrats!
Of note, reference 41 is worth checking: it seems to be either an abstract in NDT in 2020 or an original article in Am J Transplant in 2023, but not Am J Transplant 2020.